Edoxaban versus Warfarin in Patients with Atrial Fibrillation-Reference-Cited by-同舟云学术

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

Published:2013-11-28 Issue:22 Volume:369 Page:2093-2104
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Giugliano Robert P.,Ruff Christian T.,Braunwald Eugene,Murphy Sabina A.,Wiviott Stephen D.,Halperin Jonathan L.,Waldo Albert L.,Ezekowitz Michael D.,Weitz Jeffrey I.,Špinar Jindřich,Ruzyllo Witold,Ruda Mikhail,Koretsune Yukihiro,Betcher Joshua,Shi Minggao,Grip Laura T.,Patel Shirali P.,Patel Indravadan,Hanyok James J.,Mercuri Michele,Antman Elliott M.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1310907

Cited by 4300 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atrial fibrillation management in older hospitalized patients: Evidence of a poor oral anticoagulants prescriptive attitude from the Italian REPOSI registry;Archives of Gerontology and Geriatrics;2025-01

2. The use of reduced DOAC doses in atrial fibrillation patients does not always lead to good anticoagulation levels and avoid adverse events;International Journal of Cardiology;2024-12

3. Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design;American Heart Journal;2024-11

4. Can edoxaban be used at extremes of bodyweight and in patients with a creatinine clearance ≥95 ml/min? – A population pharmacokinetic analysis;Thrombosis Research;2024-10

5. Antiplatelet Therapy in Patients Requiring Oral Anticoagulation and Undergoing Percutaneous Coronary Intervention;Interventional Cardiology Clinics;2024-10